Role of Vitamin D supplementation in the treatment response for parthenium dermatitis
Phase 4
Completed
- Conditions
- Health Condition 1: null- Parthenium dermatitis patients with Vitamin D deficiency
- Registration Number
- CTRI/2016/02/006626
- Lead Sponsor
- JIPMER Intramural fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 72
Inclusion Criteria
Clinically diagnosed Parthenium dermatitis patients to be started on systemic treatment with azathioprine
Vitamin D deficiency (10-20 ng/ml)
Exclusion Criteria
Pregnant and lactating women
Individuals already on vitamin D supplementation
Liver dysfunction (AST, ALT > 1.5 times the upper limit of normal)
Renal dysfunction (Serum creatinine, blood urea > 1.5 times the upper limit of normal)
Patients who had participated in other trials within last 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IL-10 levels, disease severity scoring (EASI-Erythema Area Severity Index)Timepoint: IL-10 - At baseline and after 2 months <br/ ><br>Disease severity - At baseline, At the end of 1st month, 2nd month and 3rd month
- Secondary Outcome Measures
Name Time Method Adherence to medicationTimepoint: At the end of each month till six months;Frequency of relapsesTimepoint: At the end of each month till six months;Need for rescue medicationsTimepoint: At the end of each month till six months;Quality of life indexTimepoint: At baseline, At the end of 1st month, 2nd month and 3rd month